Searched for
BREAST CANCER BIOSIMILAR
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Sun Pharma looks to outshine rival bids with $13 billion Organon offerSun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...
- Zydus Lifesciences introduces biosimilar to protect bone health in cancer patientsZydus Lifesciences has launched Zyrifa, a Denosumab biosimilar, for treating osteoporosis and preventing skeletal complications in cancer p...
- Alkem launches breast cancer biosimilar in IndiaAlkem Laboratories has launched Pertuza, a biosimilar of pertuzumab, in India for treating HER2-positive breast cancer. This indigenously d...
- Zydus gets Mexican regulatory approval to market cancer treatment productThe product is used in the treatment of breast cancer and advanced gastric cancer. Breast cancer has become the most diagnosed cancer in Me...
- Zydus Cadila launches breast cancer treatment drug Ujvira"In a step that can significantly reduce treatment cost by almost 80 per cent, the drug is being offered at Rs 32,495 for a 100 mg vial. Th...
- Biocon Biologics, Viatris receive approval for cancer drugAbevmy is approved for treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma,...
- Biocon, Mylan launch cancer drug in US marketOgivri, available in a 420mg multi-dose vial and a 150mg single-dose vial, will be used for treatment of all types of breast cancer and met...
- Dr Reddy's launches Hervycta to treat cancer in IndiaQuoting Ipsos data, the company said the Herceptin and its biosimilars had India sales of Rs 290 crore for the most recent 12 months ending...
- Mylan-Biocon's breast cancer biosimilar gets ANVISA nodBiosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan.
- Biocon's pain could continue post EU drug application withdrawalBiocon shares tanked 5.9 per cent to Rs 328.80 at the close on the BSE on Wednesday.
- Big boost for Biocon as USFDA Onco committee approves company's first breast cancer biosimilar drugThe USFDA's Oncology Drugs Advisory Committee voted 16-0 in support of the eligible indications of the original product.
- CCI to investigate Swiss drugmaker Roche over breast cancer biosimilarCCI’s action is in response to a complaint filed by Mylan and Biocon, who have together developed biosimilar version of Roche’s blockbuster...
- Delhi High Court gives Biocon, Mylan green light to market blockbuster biosimilar for three cancersThe court’s latest move, which allows the companies to use Roche’s product data in their package inserts, is expected to allow Biocon and M...
- USFDA accepts Mylan's application for proposed biosimilar TrastuzumabThis is Mylan and Biocon's "first US regulatory submission through the 351(k) pathway and reinforces the strength of collaboration."
- Mylan launches breast cancer drug in IndiaDrug major Mylan Inc today said it has launched breast cancer drug Hertraz Herceptin in India.
- Biocon gets DCGI nod to market biosimilar trastuzumab in IndiaBiocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan.
- Biocon gets DCGI nod to market biosimilar trastuzumab in IndiaBiocon said it has received approval to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.
Load More
